Nurix Therapeutics is an American biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. Nurix Therapeutics was founded in 2009 and is headquartered in San Francisco, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Nurix Therapeutics news
08.07.2022
Nurix Therapeutics' GAAP loss for 6 months of fiscal year 2022 was $87.934 million, up 73.6% from $50.657 million in the prior year. Revenue increased 74% to $21.053 million compared to $12.102 million a year earlier.
Source: 
ir.nurixtx.com
ir.nurixtx.com
08.04.2022
Nurix Therapeutics' GAAP loss for 3 months of fiscal year 2022 was $42.533 million, up 75.2% from $24.275 million in the prior year. Revenue increased 92% to $9.621 million from $5.011 million a year earlier.
Source: ir.nurixtx.com
ir.nurixtx.com
28.01.2022
Nurix Therapeutics' GAAP loss for 2021 was $117.194 million, up 2.7 times from $43.242 million in the previous year. Revenue increased 66.9% to $29.75 million from $17.82 million a year earlier.
Source: ir.nurixtx.com
ir.nurixtx.com
15.10.2021
Nurix Therapeutics' GAAP loss for 9M 2021 was $79.492 million, up 3.4 times from $23.328 million in the previous year. Revenue doubled to $22.354 million from $11.131 million a year earlier.
Source: ir.nurixtx.com
ir.nurixtx.com
General information
| Company name | Nurix Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 1700 Owens Street Suite 205 San Francisco, CA 94158 United States |
| Mailing address | 1700 Owens Street Suite 205 San Francisco, CA 94158 United States |
| Website | ir.nurixtx.com |
| Information disclosure | www.sec.gov |
English (US) 